LAKE FOREST, Ill. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings , Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that President, chief executive officer and director, Todd Smith will present at and participate in investor meetings at

Reported Net Product Sales of $34.3 Million   Non-GAAP Net Product Sales of $33.7 Million ; Increased 21.4% over Pro-Forma Second Quarter 2020 Non-GAAP Net Product Sales Consistent with Pro-Forma Prior Year Quarter Despite COVID-19 Related Sales Disruptions and Effects of Sales Force Integration

LAKE FOREST, Ill. , Oct. 23, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its third quarter 2020 financial results will be released on Friday, November 6, 2020 .

LAKE FOREST, Ill. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that the company will present at and participate in investor meetings at the Cantor Virtual Global Healthcare Conference

--Completed all merger and integration activities in Q2-- --Repaid $10 million of Senior Secured Notes ahead of schedule-- --Zyla products partially contributed to Q2 net product sales of $20.2 million -- --Combined second quarter 2020 net product sales of $27.7 million , on a pro forma basis,

LAKE FOREST, Ill. , July 20, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its second quarter 2020 financial results will be released on Friday, August 7, 2020 .

Trading under ASRT on Nasdaq Global Select Market Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million¹ Upwards of $40 million in Expected Cost Synergies LAKE FOREST, Ill. , May 20, 2020 /PRNewswire/ -- Assertio Holdings, Inc., the successor issuer to Assertio

-- Completed Strategic Asset Sales of NUCYNTA ® Franchise and Gralise ® Totaling $502.5 Million -- -- Repaid Senior Secured Debt in Full and Successfully Tendered for Convertible Debt -- -- Merger with Zyla Life Sciences On Track and Expected to Close Shortly After the Company’s 2020 Annual Meeting

 Merger with Zyla Life Sciences Expected to Close Shortly After the 2020 Annual Meeting Assertio Reaffirms its Ability to Achieve Upwards of $40 Million in Synergies Will Report First Quarter 2020 Financial Results on Monday, May 11, 2020 Prior to the Open of Markets LAKE FOREST, Ill.

LAKE FOREST, Ill. , April 08, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announced the completion and final results for its cash tender offers (the “Offers”) to purchase any and all of the outstanding $42,465,000 in aggregate principal